UNSPSC 51182012: Androstenolone or dehydroepiandrosterone or DHEA or prasterone

This classification denotes a therapeutic androgen, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 459AG36T1B. European Medicines Agency schedules Dehydroepiandrosterone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10002MIG. Prasterone generally arises in the molecular formula C19H28O2.

The term PRASTERONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, no 10 1978, list 18.) PRASTERONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O=C1C2(C(C3C(C4(C(=CC3)CC(O)CC4)C)CC2)CC1)C.

UNSPSC 51182012 Androstenolone or dehydroepiandrosterone or DHEA or prasterone is a Commodity code encompassing pharmaceutical preparations of specific steroid hormones used in pharmaceutical supply chains serving state and local government health facilities. State and local jurisdictions procure these products through cooperative purchasing agreements and direct pharmaceutical supply contracts to support public health, hospital, and clinical operations. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents a primary issuing body for multi-source pharmaceutical procurement vehicles that span state agencies, local government facilities, and participating jurisdictions including Oregon. Procurement under this code typically flows through established cooperative frameworks and authorized pharmaceutical wholesalers rather than direct vendor engagement with individual municipalities or counties, reducing fragmentation across jurisdictions seeking bulk pharmaceutical supplies.

MMCAP issued a Request for Proposal (RFP) on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products with a response deadline of March 26, 2026. The solicitation requires manufacturers to supply identified pharmaceutical products with specific National Drug Codes (NDC), maintain current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) compliance, and work through three authorized wholesalers: AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. Vendors must demonstrate pricing flexibility through flat price, net price formats, or WAC-minus structures, with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing stability, and 5 percent each on administrative compliance, EDI capability, and acceptance of a 3 percent administrative fee. The contract term spans two years for new responders with optional MMCAP extensions, becoming effective July 1, 2026, with products required in the marketplace by May 15, 2026.